Multiple Endocrine Neoplasia Type 2a

This is another inherited genetic condition that causes tumors in specific glands. It mainly affects the thyroid gland (causing a specific type of thyroid cancer) and the adrenal glands (causing tumors that produce hormones). It can also sometimes affect the parathyroid glands. It's caused by a change in a gene called RET.

ConditionRare Disease

What people with Multiple Endocrine Neoplasia Type 2a report

Every report comes from a Lived member, sent anonymously.

Have you had Thyroid Surgery for Multiple Endocrine Neoplasia Type 2a?

NameHow it went

About Multiple Endocrine Neoplasia Type 2a

What It Is

Multiple endocrine neoplasia type 2A (MEN2A) is an inherited condition that makes tumors likely to develop in several hormone-producing glands. Its defining feature is a form of thyroid cancer called medullary thyroid cancer, which nearly everyone with MEN2A develops at some point if the thyroid is left in place. Up to half also develop a pheochromocytoma, an adrenal gland tumor that releases adrenaline-like hormones and can drive blood pressure dangerously high. About a quarter develop overactive parathyroid glands, which raises blood calcium. MEN2A matters because these tumors can be found, and often prevented, long before they cause symptoms. Medullary thyroid cancer in MEN2A usually appears in early adulthood, but the timing depends on the exact genetic change a family carries. MEN2A is the most common form of MEN type 2. It is different from MEN2B, which causes earlier and more aggressive thyroid cancer, and from MEN1, which involves different glands and a different gene. Some families also have itchy, thickened skin patches on the upper back (cutaneous lichen amyloidosis) or, less often, Hirschsprung disease, a bowel problem present from birth.

Causes & Risk Factors

MEN2A is caused by a change (variant) in the RET gene. RET normally helps tell cells when to grow, and the variants that cause MEN2A switch it on when it should be off, so cells in the thyroid, adrenal and parathyroid glands tend to multiply and form tumors. Nothing a person does causes or triggers the condition. MEN2A is inherited in an autosomal dominant pattern: one altered copy of the gene is enough, and each child of someone with MEN2A has a 50% chance of inheriting it. Most people with MEN2A have an affected parent, while a small share (roughly 5 to 9%) have a new variant that arose for the first time in them. The specific RET variant strongly predicts how early thyroid cancer is likely to start and how likely a pheochromocytoma is, although people with the same variant can still follow different courses.

How It's Diagnosed

MEN2A is diagnosed either because someone develops its typical tumors or, more often today, because a genetic blood test finds a disease-causing RET variant. Once a variant is known in one person, relatives can be tested for that exact change. A negative result in a relative from a family with a known variant means they do not need the special monitoring, which is a large part of why family testing is so useful. Blood tests then show what, if anything, is already active. Calcitonin is a hormone made by the thyroid cells that give rise to medullary thyroid cancer; a rising level suggests cancer is developing or has returned. Metanephrines, breakdown products of adrenaline-type hormones measured in blood or a 24-hour urine collection, screen for pheochromocytoma. Blood calcium checks for overactive parathyroid glands. Imaging, such as an ultrasound of the neck or a scan of the adrenal glands, helps locate tumors when blood tests are abnormal.

Treatment Options

The central treatment is removing the thyroid (thyroidectomy) before medullary thyroid cancer has a chance to spread. For people found through genetic testing, surgeons time this preventive surgery by the family's RET variant and the calcitonin level: in the highest-risk families this can mean early childhood, while others can be watched with regular blood tests and have surgery when calcitonin begins to rise. Done early enough, this surgery has made a historically fatal cancer curable for many families. When cancer is already present, the operation usually also removes nearby lymph nodes. Afterward, people take thyroid hormone (levothyroxine, such as Synthroid) every day for life. A pheochromocytoma must be looked for before any operation and, if found, removed first, because surgery or anesthesia with an untreated tumor can cause a dangerous surge in blood pressure. Before adrenal surgery, people take medicines to bring blood pressure and heart rate under control. Overactive parathyroid glands are usually treated by removing the enlarged gland or glands. If medullary thyroid cancer has spread and is growing, targeted pills called kinase inhibitors can slow it. Selpercatinib (Retevmo) is approved for advanced medullary thyroid cancer with a RET variant in adults and children 2 and older. These medicines control disease rather than cure it, and need ongoing monitoring for side effects.

What to Expect

MEN2A is lifelong, but for people diagnosed through family testing, the outlook is far better than it once was. Many have their thyroid removed before cancer develops and then live with a routine of daily thyroid hormone and yearly check-ups. Those check-ups matter even after surgery. Calcitonin is measured each year to catch any thyroid cancer that remains or returns. Metanephrines are checked yearly for pheochromocytoma, and calcium for parathyroid overactivity, starting at an age set by the family's RET variant. Pheochromocytomas can come back after removal, so monitoring continues even after adrenal surgery. A few practical points follow from the pheochromocytoma risk. Anyone with MEN2A planning a pregnancy should be screened beforehand, or as early as possible in an unplanned pregnancy, since an undiscovered tumor can cause dangerous blood pressure surges during pregnancy and delivery. It is also worth making sure every clinician knows about MEN2A: beta blockers (a common heart and blood pressure medicine) and some anti-nausea and antipsychotic medicines that block dopamine can provoke serious reactions if a pheochromocytoma is present. Because MEN2A runs in families, a diagnosis often affects parents, siblings and children too. Genetic counseling helps with telling relatives, testing children and family planning choices.

When to Seek Help

If a close relative has MEN2A or medullary thyroid cancer, ask about genetic counseling and RET testing, ideally before children reach the age when preventive surgery might be needed. If you have MEN2A, keep yearly testing on schedule and see your care team for a new lump in the neck or a calcium result outside the normal range. Contact your care team soon about spells of headache, heavy sweating and a pounding heartbeat, newly high blood pressure, or the return of symptoms after a pheochromocytoma was removed, since these can signal an active adrenal tumor. Tell your care team about MEN2A before any surgery, pregnancy or new heart or anti-nausea medicine.

Questions to Ask Your Doctor

  1. 1.Which RET variant does our family carry, and what does it mean for the timing of thyroid surgery and screening?
  2. 2.Based on my calcitonin level, should I have my thyroid removed now or keep monitoring?
  3. 3.At what age should my children be tested, and what happens if they carry the variant?
  4. 4.How often will I need blood tests and scans, and what result would change the plan?
  5. 5.What should other doctors know about MEN2A before surgery, pregnancy or new medicines?

Last reviewed • Oct 2026

Educational content, not medical advice.